Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Candida auris, a multidrug-resistant yeast that causes invasive infections, was first described in 2009 in Japan and has since been reported from several countries. METHODS: To understand the global emergence and epidemiology of C. auris, we obtained isolates from 54 patients with C. auris infection from Pakistan, India, South Africa, and Venezuela during 2012-2015 and the type specimen from Japan. Patient information was available for 41 of the isolates. We conducted antifungal susceptibility testing and whole-genome sequencing (WGS). RESULTS: Available clinical information revealed that 41% of patients had diabetes mellitus, 51% had undergone recent surgery, 73% had a central venous catheter, and 41% were receiving systemic antifungal therapy when C. auris was isolated. The median time from admission to infection was 19 days (interquartile range, 9-36 days), 61% of patients had bloodstream infection, and 59% died. Using stringent break points, 93% of isolates were resistant to fluconazole, 35% to amphotericin B, and 7% to echinocandins; 41% were resistant to 2 antifungal classes and 4% were resistant to 3 classes. WGS demonstrated that isolates were grouped into unique clades by geographic region. Clades were separated by thousands of single-nucleotide polymorphisms, but within each clade isolates were clonal. Different mutations in ERG11 were associated with azole resistance in each geographic clade. CONCLUSIONS: C. auris is an emerging healthcare-associated pathogen associated with high mortality. Treatment options are limited, due to antifungal resistance. WGS analysis suggests nearly simultaneous, and recent, independent emergence of different clonal populations on 3 continents. Risk factors and transmission mechanisms need to be elucidated to guide control measures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“C. auris, a novel Candida species first identified in 2009, has emerged since 2013 as a cause of nosocomial outbreaks in multiple countries across 5 continents.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [16]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resistance to all three classes of antifungals is reported most commonly in India in South Asia (3%), whereas this is much less common in other regions of the world.122–124”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [122]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Invasive C. auris infections are associated with high mortality rates, with 60% of hospitalizations due to C. auris infections resulting in death (8).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three such mutations, encoding the amino acid substitutions VF125AL (commonly referred to as F126L), Y132F, and K143R, are frequently reported among fluconazole-resistant clinical isolates, and associations between these mutations and specific genetic clades of C. auris have been observed (2).”
From Mutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, up to 96% of C. auris may exhibit resistance to fluconazole, an exceptionally high value compared to 0.5–2% for C. albicans, 4–9% for C. tropicalis, 2–6% for C. parapsilosis, and 11–13% for C. glabrata [16,40,41].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [16]
Experimental — accuracy not yet measured
29 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0
Tamura, K., Stecher, G., Peterson, D., Filipski, A., & Kumar, S. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst197 · Cited by 47,205
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895 · cited 1×
“SNPs were identified using 2 independent pipelines, as described elsewhere (see also the legend to Supplemental Figure 1) [15, 19].”
MethodEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“auris because we did not have a comparison group of patients with other Candida infections from the same institutions [31].”
BackgroundResultNonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data
Chin, C.-S., Alexander, D. H., Marks, P., Klammer, A. A., Drake, J., Heiner, C., Clum, A., Copeland, A., Huddleston, J., Eichler, E. E., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2474 · Cited by 4,029 · cited 1×
“The reference genome was generated by de novo assembly of PacBio reads from isolate B8441, as described elsewhere [18], and used as a reference for single-nucleotide polymorphism (SNP) calling.”
MethodSatoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381 · cited 8×
“To understand the global emergence and epidemiology of C. auris, we obtained isolates from 54 patients with C. auris infection from Pakistan, India, South Africa, and Venezuela during 2012–2015 and the type specimen from Japan.”
BackgroundInfluentialEvolution of pathogenicity and sexual reproduction in eight Candida genomes
Butler, G., Rasmussen, M. D., Lin, M. F., Santos, M. A. S., Sakthikumar, S., Munro, C. A., Rheinbay, E., Grabherr, M., Forche, A., Reedy, J. L., et al. (2009) · Nature · doi:10.1038/nature08064 · Cited by 1,065 · cited 1×
“5 Mb, similar to that of other Candida species [25].”
BackgroundSelf-citationKathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532 · cited 1×
“It phenotypically resembles Candida haemulonii and requires use of molecular methods for identification [9, 10].”
MethodSelf-citationFirst Three Reported Cases of Nosocomial Fungemia Caused by Candida auris
Lee, W. G., Shin, J. H., Uh, Y., Kang, M. G., Kim, S. H., Park, K. H., & Jang, H.-C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00319-11 · Cited by 523 · cited 2×
“auris [3], establishing that this new species was capable of causing invasive infections.”
BackgroundPerea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470
Incidence, characteristics and outcome of ICU-acquired candidemia in India
Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., Kaur, H., Capoor, M., Chhina, D., Rao, R., Eshwara, V. K., Xess, I., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-014-3603-2 · Cited by 454 · cited 1×
“auris may become widely established within certain regions, as evidenced by the fact that it now accounts for nearly 5% of candidemia in Indian intensive care units [5].”
Background
Cited by
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636
Worldwide emergence of resistance to antifungal drugs challenges human health and food security
Fisher, M. C., Hawkins, N. J., Sanglard, D., & Gurr, S. J. (2018) · Science · doi:10.1126/science.aap7999 · Cited by 1,555
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
“S90 • OFID 2019:6 (Suppl 1) • Pfaller et al SENTRY Program Candida Surveillance (1997–2016) • OFID 2019:6 (Suppl 1) • S91 [93, 94], and emerging resistance mechanisms [20, 68] highlight the importance of local and global surveillance studies.”
BackgroundSelf-citationAntifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
First hospital outbreak of the globally emerging Candida auris in a European hospital
Schelenz, S., Hagen, F., Rhodes, J. L., Abdolrasouli, A., Chowdhary, A., Hall, A., Ryan, L., Shackleton, J., Trimlett, R., Meis, J. F., et al. (2016) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-016-0132-5 · Cited by 768
“auris isolates in the same geographic areas [14, 15].”
BackgroundSelf-citationChowdhary, A., Sharma, C., & Meis, J. F. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006290 · Cited by 750
Self-citationSims, N., & Kasprzyk-Hordern, B. (2020) · Environment International · doi:10.1016/j.envint.2020.105689 · Cited by 665
“For example, Candida auris, an emerging multidrug resistant yeast, is a cause of major hospital acquired infection with high associated mortality, having only first been identified in 2009 it has resistance to all clinically available antifungals (Lockhart et al., 2017) .”
Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
“Prevention strategies to limit development of MDR and XDR infections are critical.”
BackgroundInfluentialResistance of Candida to azoles and echinocandins worldwide
Pristov, K. E., & Ghannoum, M. A. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.03.028 · Cited by 706
“auris, as well as other Candida species, from environmental surfaces and reusable equipment in healthcare facilities, implying that contaminated surfaces may be the source of transmission [45,53].”
BackgroundDrug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Candida auris: a Review of the Literature
Jeffery-Smith, A., Taori, S. K., Schelenz, S., Jeffery, K., Johnson, E. M., Borman, A., Candida auris Incident Management Team, Manuel, R., & Brown, C. S. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-17 · Cited by 595
“Increased fluconazole MICs, in a high proportion of cases ( 64 mg/liter), have been demonstrated to be present in all geographic clusters (7, 8, 10, 20, 22, 27, 41, 43), but resistance is not ubiquitous (5, 6, 9).”
BackgroundInfluentialCandida auris: Epidemiology, biology, antifungal resistance, and virulence
Du, H., Bing, J., Hu, T., Ennis, C. L., Nobile, C. J., & Huang, G. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008921 · Cited by 609
“The genome of C. auris B8441 was sequenced by the CDC [10], and its sequence information and annotation is available on the Candida Genome Database (CGD) database (https://www.candidagenome.org).”
BackgroundMethodInfluentialThreats Posed by the Fungal Kingdom to Humans, Wildlife, and Agriculture
Fisher, M. C., Gurr, S. J., Cuomo, C. A., Blehert, D. S., Jin, H., Stukenbrock, E. H., Stajich, J. E., Kahmann, R., Boone, C., Denning, D. W., et al. (2020) · mBio · doi:10.1128/mbio.00449-20 · Cited by 536
“Infected patient populations, while not generally immunocompromised, often have other major health complications or have undergone recent invasive procedures (47).”
BackgroundInfluentialSelf-citationChowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577
Self-citationAntifungal drug resistance: evolution, mechanisms and impact
Revie, N. M., Iyer, K. R., Robbins, N., & Cowen, L. E. (2018) · Current Opinion in Microbiology · doi:10.1016/j.mib.2018.02.005 · Cited by 516
Changes in the epidemiological landscape of invasive candidiasis
Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx444 · Cited by 547
Self-citationFluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
“All of this information culminates in the conclusion that the point mutations in the target protein play a role in the fluconazoleresistant phenotype of these isolates.(23)”
BackgroundSelf-citationLücking, R., Aime, M. C., Robbertse, B., Miller, A. N., Ariyawansa, H. A., Aoki, T., Cardinali, G., Crous, P. W., Druzhinina, I. S., Geiser, D. M., et al. (2020) · IMA Fungus · doi:10.1186/s43008-020-00033-z · Cited by 504
“The emerging multi-drug resistant yeast Candida auris is one example of a fungus misidentified by phenotypic tools (Chatterjee et al. 2015; Lockhart et al. 2017).”
BackgroundA Candida auris Outbreak and Its Control in an Intensive Care Setting
Eyre, D. W., Sheppard, A. E., Madder, H., Moir, I., Moroney, R., Quan, T. P., Griffiths, D., George, S., Butcher, L., Morgan, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714373 · Cited by 517
The scope of the antimicrobial resistance challenge
Okeke, I. N., de Kraker, M. E. A., Van Boeckel, T. P., Kumar, C. K., Schmitt, H., Gales, A. C., Bertagnolio, S., Sharland, M., & Laxminarayan, R. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00876-6 · Cited by 474
On the emergence of Candida auris: climate change, azoles, swamps, and birds
Casadevall, A., Kontoyiannis, D. P., & Robert, V. (2019) · mBio · doi:10.1128/mbio.01397-19 · Cited by 515
Welsh, R. M., Bentz, M. L., Shams, A., Houston, H., Lyons, A., Rose, L. J., & Litvintseva, A. P. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00921-17 · Cited by 499
“Asia (India/Pakistan), Africa, South America, and East Asia (Korea/Japan) show four highly clonal phylogenetic and geographically distinct clades that have emerged independently of one another (9).”
BackgroundSelf-citationAntifungal resistance: current trends and future strategies to combat
Wiederhold, N. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s124918 · Cited by 468
“In a recent retrospective review of the clinical history of 54 patients, most had multiple risk factors for invasive disease and candidemia was observed in 61%.(7) Strikingly, the mortality rate in this series of patients was 59%.”
InfluentialChow, N. A., Muñoz, J. F., Gade, L., Berkow, E., Li, X., Welsh, R. M., Forsberg, K., Lockhart, S. R., Adam, R., Alanio, A., et al. (2020) · doi:10.1101/2020.01.06.896548 · Cited by 463
Self-citationMuñoz, J. F., Gade, L., Chow, N. A., Loparev, V. N., Juieng, P., Berkow, E. L., Farrer, R. A., Litvintseva, A. P., & Cuomo, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-07779-6 · Cited by 458
Self-citationELLWANGER, J. H., KULMANN-LEAL, B., KAMINSKI, V. L., VALVERDE-VILLEGAS, J. M., VEIGA, A. B. G. D., SPILKI, F. R., FEARNSIDE, P. M., CAESAR, L., GIATTI, L. L., WALLAU, G. L., et al. (2020) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765202020191375 · Cited by 413
Candida auris : The recent emergence of a multidrug-resistant fungal pathogen
Forsberg, K., Woodworth, K., Walters, M., Berkow, E. L., Jackson, B., Chiller, T., & Vallabhaneni, S. (2019) · Medical Mycology · doi:10.1093/mmy/myy054 · Cited by 421
“Although studies have reported therapeutic outcomes, 1,8,15 no systematic study has assessed effectiveness of various antifungals against C. auris infections in humans.”
BackgroundSelf-citationAntifungal Susceptibility Testing: Current Approaches
Berkow, E. L., Lockhart, S. R., & Ostrosky-Zeichner, L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00069-19 · Cited by 368
Self-citationCandida auris: an Emerging Fungal Pathogen
Spivak, E. S., & Hanson, K. E. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01588-17 · Cited by 393
“WGS has also been applied to an international collection of isolates in an effort to better assess the relatedness to other Candida species and evaluate clonality among strains (12, 26).”
BackgroundInfluentialAmphotericin B and Other Polyenes—Discovery, Clinical Use, Mode of Action and Drug Resistance
Carolus, H., Pierson, S., Lagrou, K., & Van Dijck, P. (2020) · Journal of Fungi · doi:10.3390/jof6040321 · Cited by 349
“auris, in which an AmB resistance prevalence of up to 30% [81-83] has been found among clinical isolates, but still sequencing efforts cannot identify driving mutations.”
BackgroundEmerging Fungal Infections: New Patients, New Patterns, and New Pathogens
Friedman, D. Z. P., & Schwartz, I. S. (2019) · Journal of Fungi · doi:10.3390/jof5030067 · Cited by 357
Candida auris candidaemia in Indian ICUs: analysis of risk factors
Rudramurthy, S. M., Chakrabarti, A., Paul, R. A., Sood, P., Kaur, H., Capoor, M. R., Kindo, A. J., Marak, R. S. K., Arora, A., Sardana, R., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx034 · Cited by 357
Potential Fifth Clade of Candida auris, Iran, 2018
Chow, N. A., de Groot, T., Badali, H., Abastabar, M., Chiller, T. M., & Meis, J. F. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2509.190686 · Cited by 356
“auris has identified 4 major populations in which isolates cluster by geography (4).”
BackgroundSelf-citationRuiz‐Gaitán, A., Moret, A. M., Tasias‐Pitarch, M., Aleixandre‐López, A. I., Martínez‐Morel, H., Calabuig, E., Salavert‐Lletí, M., Ramírez, P., López‐Hontangas, J. L., Hagen, F., et al. (2018) · Mycoses · doi:10.1111/myc.12781 · Cited by 343
Self-citationEpidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris
Cortegiani, A., Misseri, G., Fasciana, T., Giammanco, A., Giarratano, A., & Chowdhary, A. (2018) · Journal of Intensive Care · doi:10.1186/s40560-018-0342-4 · Cited by 329
Self-citationMorbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis
Koehler, P., Stecher, M., Cornely, O. A., Koehler, D., Vehreschild, M. J. G. T., Bohlius, J., Wisplinghoff, H., & Vehreschild, J. J. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.04.024 · Cited by 336
Lass-Flörl, C., Kanj, S. S., Govender, N. P., Thompson, G. R., Ostrosky- Zeichner, L., & Govrins, M. A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00503-3 · Cited by 298
Self-citationThe rapid emergence of antifungal-resistant human-pathogenic fungi
Lockhart, S. R., Chowdhary, A., & Gold, J. A. W. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00960-9 · Cited by 308
Self-citationOsei Sekyere, J. (2018) · MicrobiologyOpen · doi:10.1002/mbo3.578 · Cited by 300
“Notably, they resulted in very high crude mortalities (72%; 13/18) and also shared the same FLZ resistance mechanism (Y132F and K143R in ERG11) as that of the Indian strains (Lockhart et al., 2017).”
BackgroundMethodResultInfluentialGlobal epidemiology of emerging Candida auris
Rhodes, J., & Fisher, M. C. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.05.008 · Cited by 315
Vallabhaneni, S., Kallen, A., Tsay, S., Chow, N., Welsh, R., Kerins, J., Kemble, S. K., Pacilli, M., Black, S. R., Landon, E., et al. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6544e1 · Cited by 302
Self-citationDrug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Arastehfar, A., Gabaldón, T., Garcia-Rubio, R., Jenks, J. D., Hoenigl, M., Salzer, H. J. F., Ilkit, M., Lass-Flörl, C., & Perlin, D. S. (2020) · Antibiotics · doi:10.3390/antibiotics9120877 · Cited by 292
Chow, N. A., Gade, L., Tsay, S. V., Forsberg, K., Greenko, J. A., Southwick, K. L., Barrett, P. M., Kerins, J. L., Lockhart, S. R., Chiller, T. M., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30597-8 · Cited by 289
Self-citationCandida auris in Healthcare Facilities, New York, USA, 2013–2017
Adams, E., Quinn, M., Tsay, S., Poirot, E., Chaturvedi, S., Southwick, K., Greenko, J., Fernandez, R., Kallen, A., Vallabhaneni, S., et al. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2410.180649 · Cited by 284
“, Bair hugger) 20 1 (5) 0 19 (95) Computer workstation 20 0 0 20 (100) Thermometer 14 1 (7) 1 (7) 12 (86) PPE/isolation cart/box 12 1 (8) 1 (8) 10 (83) Lift/scale 11 2 (18) 0 9 (82) Glucometer 11 0 0 11 (100) Housekeeping cart 9 0 1 (11) 8 (89) Dialysis equipment 7 1 (14) 0 6 (86) Suction canister 6 1 (17) 0 5 (83) Ul…”
BackgroundSelf-citationPathogen Genomics in Public Health
Armstrong, G. L., MacCannell, D. R., Taylor, J., Carleton, H. A., Neuhaus, E. B., Bradbury, R. S., Posey, J. E., & Gwinn, M. (2019) · New England Journal of Medicine · doi:10.1056/nejmsr1813907 · Cited by 263
Immune defence to invasive fungal infections: A comprehensive review
Pathakumari, B., Liang, G., & Liu, W. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110550 · Cited by 264
Arendrup, M. C., Prakash, A., Meletiadis, J., Sharma, C., & Chowdhary, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00485-17 · Cited by 270
“The ethanol-formic acid extraction procedure was performed according to the manufacturer’s protocol for the identification of yeast isolates (2, 5).”
BackgroundMethodResultSelf-citationAhmad, S., & Alfouzan, W. (2021) · Microorganisms · doi:10.3390/microorganisms9040807 · Cited by 269
“However, tentative breakpoints have been suggested by the Centers for Disease Control and prevention (CDC) based on expert opinion and those established for other closely related Candida species [62,72,73,89,155,156].”
BackgroundInfluentialThe Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors
Zhang, J., Li, L., Lv, Q., Yan, L., Wang, Y., & Jiang, Y. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00691 · Cited by 245
“It is worth noting that drug resistance is often a combination of multiple mechanisms (Berkow and Lockhart, 2017).”
BackgroundCandidemia and Invasive Candidiasis
McCarty, T. P., White, C. M., & Pappas, P. G. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.007 · Cited by 260
“50 Among 35 iso-lates in the United States, 30 (86”
Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris
Kordalewska, M., Lee, A., Park, S., Berrio, I., Chowdhary, A., Zhao, Y., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00238-18 · Cited by 247
“Comparable levels of resistance (2% and 7%, respectively) were reported for C. auris isolates collected in India (10 hospitals) and by the CDC (from hospitals in Pakistan, India, South Africa, and Venezuela) (5, 25).”
BackgroundInfluentialSelf-citationVallabhaneni, S., Kallen, A., Tsay, S., Chow, N., Welsh, R., Kerins, J., Kemble, S. K., Pacilli, M., Black, S. R., Landon, E., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14121 · Cited by 247
Self-citationGenomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris
Rhodes, J., Abdolrasouli, A., Farrer, R. A., Cuomo, C. A., Aanensen, D. M., Armstrong-James, D., Fisher, M. C., & Schelenz, S. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0045-x · Cited by 246
“auris genome B8441 assembled by Lockhart et al.(1) Further analysis revealed that the unmapped 1.”
BackgroundMethodInfluentialSelf-citationEvolution of the human pathogenic lifestyle in fungi
Rokas, A. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01112-0 · Cited by 232
Biswal, M., Rudramurthy, S. M., Jain, N., Shamanth, A. S., Sharma, D., Jain, K., Yaddanapudi, L. N., & Chakrabarti, A. (2017) · Journal of Hospital Infection · doi:10.1016/j.jhin.2017.09.009 · Cited by 223
The importance of antimicrobial resistance in medical mycology
Gow, N. A. R., Johnson, C., Berman, J., Coste, A. T., Cuomo, C. A., Perlin, D. S., Bicanic, T., Harrison, T. S., Wiederhold, N., Bromley, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32249-5 · Cited by 224
Self-citationEvolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
“, Y132F, K143R, and F126T), which has been implicated in reduced azole susceptibility in other species [16].”
BackgroundApplication of Next Generation Sequencing in Laboratory Medicine
Zhong, Y., Xu, F., Wu, J., Schubert, J., & Li, M. M. (2021) · Annals of Laboratory Medicine · doi:10.3343/alm.2021.41.1.25 · Cited by 215
Antifungal drugs: What brings the future?
Van Daele, R., Spriet, I., Wauters, J., Maertens, J., Mercier, T., Van Hecke, S., & Brüggemann, R. (2019) · Medical Mycology · doi:10.1093/mmy/myz012 · Cited by 223
Essential Oils of Lamiaceae Family Plants as Antifungals
Karpiński, T. M. (2020) · Biomolecules · doi:10.3390/biom10010103 · Cited by 202
“About 30% of isolates demonstrate reduced susceptibility to amphotericin B, and 5% can be resistant to the echinocandins [19,20].”
BackgroundEnvironmental Isolation of Candida auris from the Coastal Wetlands of Andaman Islands, India
Arora, P., Singh, P., Wang, Y., Yadav, A., Pawar, K., Singh, A., Padmavati, G., Xu, J., & Chowdhary, A. (2021) · mBio · doi:10.1128/mbio.03181-20 · Cited by 223
Self-citationReview on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris
Chaabane, F., Graf, A., Jequier, L., & Coste, A. T. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02788 · Cited by 223
“All clades are characterized by distinct single nucleotide polymorphisms (SNPs), which highlights the independent and worldwide emergence of this pathogen (Lockhart et al., 2017).”
BackgroundEscandón, P., Chow, N. A., Caceres, D. H., Gade, L., Berkow, E. L., Armstrong, P., Rivera, S., Misas, E., Duarte, C., Moulton-Meissner, H., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy411 · Cited by 222
“Here, the proportion resistant to azoles and echinocandins was lower than to those from other countries examined in previous studies [2].”
BackgroundMethodResultInfluentialSelf-citationKean, R., Delaney, C., Sherry, L., Borman, A., Johnson, E. M., Richardson, M. D., Rautemaa-Richardson, R., Williams, C., & Ramage, G. (2018) · mSphere · doi:10.1128/msphere.00334-18 · Cited by 220
“Alarmingly, 41% of isolates have been shown to be multidrug resistant, with 4% demonstrating pan-drug resistance (4).”
BackgroundNext Generation and Other Sequencing Technologies in Diagnostic Microbiology and Infectious Diseases
Hilt, E. E., & Ferrieri, P. (2022) · Genes · doi:10.3390/genes13091566 · Cited by 199
Candida auris—the growing menace to global health
Lone, S. A., & Ahmad, A. (2019) · Mycoses · doi:10.1111/myc.12904 · Cited by 208
Invasive candidiasis: current clinical challenges and unmet needs in adult populations
Soriano, A., Honore, P. M., Puerta-Alcalde, P., Garcia-Vidal, C., Pagotto, A., Gonçalves-Bradley, D. C., & Verweij, P. E. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad139 · Cited by 190
Carolus, H., Pierson, S., Muñoz, J. F., Subotić, A., Cruz, R. B., Cuomo, C. A., & Van Dijck, P. (2021) · mBio · doi:10.1128/mbio.03333-20 · Cited by 211
Self-citationLipid Systems for the Delivery of Amphotericin B in Antifungal Therapy
Faustino, C., & Pinheiro, L. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12010029 · Cited by 203
COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022
(2022) · doi:10.15620/cdc:117915 · Cited by 182
Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species
Czajka, K. M., Venkataraman, K., Brabant-Kirwan, D., Santi, S. A., Verschoor, C., Appanna, V. D., Singh, R., Saunders, D. P., & Tharmalingam, S. (2023) · Cells · doi:10.3390/cells12222655 · Cited by 180
“Numerous species isolates have been identified as displaying resistance to several antifungals [26–28].”
BackgroundCandida auris and multidrug resistance: Defining the new normal
Lockhart, S. R. (2019) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2019.103243 · Cited by 205
Self-citationDiagnosis and Treatment of Invasive Candidiasis
Barantsevich, N., & Barantsevich, E. (2022) · Antibiotics · doi:10.3390/antibiotics11060718 · Cited by 178
Mutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris
Rybak, J. M., Muñoz, J. F., Barker, K. S., Parker, J. E., Esquivel, B. D., Berkow, E. L., Lockhart, S. R., Gade, L., Palmer, G. E., White, T. C., et al. (2020) · mBio · doi:10.1128/mbio.00365-20 · Cited by 202
“First identified in 2009, Candida auris has rapidly become a health care-associated and multidrug-resistant pathogen of global concern (1, 2).”
Self-citationKordalewska, M., Zhao, Y., Lockhart, S. R., Chowdhary, A., Berrio, I., & Perlin, D. S. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00630-17 · Cited by 195
“Since then, C. auris infections have been reported from South Korea (2, 3), India (4–6), Pakistan (5), Kuwait (7), Israel (8), South Africa (5, 9), the United Kingdom (10–12), Spain (13), the United States (14, 15), Colombia (16), and Venezuela (5, 17).”
BackgroundSelf-citationToda, M., Williams, S. R., Berkow, E. L., Farley, M. M., Harrison, L. H., Bonner, L., Marceaux, K. M., Hollick, R., Zhang, A. Y., Schaffner, W., et al. (2019) · MMWR Surveillance Summaries · doi:10.15585/mmwr.ss6808a1 · Cited by 198
“Central venous catheter in the 2 days before candidemia diagnosis 1,251 (77) 760 (74) 206 (60) 333 (67) 2,550 (73)”
Self-citationProctor, D. M., Dangana, T., Sexton, D. J., Fukuda, C., Yelin, R. D., Stanley, M., Bell, P. B., Baskaran, S., Deming, C., Chen, Q., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01383-w · Cited by 198
Self-citationThe first isolate of Candida auris in China: clinical and biological aspects
Wang, X., Bing, J., Zheng, Q., Zhang, F., Liu, J., Yue, H., Tao, L., Du, H., Wang, Y., Wang, H., et al. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0095-0 · Cited by 191
Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents
Jacobs, S. E., Jacobs, J. L., Dennis, E. K., Taimur, S., Rana, M., Patel, D., Gitman, M., Patel, G., Schaefer, S., Iyer, K., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00053-22 · Cited by 190
Intensive care medicine research agenda on invasive fungal infection in critically ill patients
Bassetti, M., Garnacho-Montero, J., Calandra, T., Kullberg, B., Dimopoulos, G., Azoulay, E., Chakrabarti, A., Kett, D., Leon, C., Ostrosky-Zeichner, L., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4731-2 · Cited by 183
“auris is an emerging, multidrug-resistant yeast causing invasive healthcare-associated infections [29].”
BackgroundSuphavilai, C., Ko, K. K. K., Lim, K. M., Tan, M. G., Boonsimma, P., Chu, J. J. K., Goh, S. S., Rajandran, P., Lee, L. C., Tan, K. Y., et al. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(24)00101-0 · Cited by 174
Self-citationAdeme, M. (2020) · doi:10.2147/idr.s249864 · Cited by 182
Emerging multidrug-resistant Candida species
Colombo, A. L., Júnior, J. N. D. A., & Guinea, J. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000411 · Cited by 177
Self-citationCandida auris: Disinfectants and Implications for Infection Control
Ku, T. S. N., Walraven, C. J., & Lee, S. A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00726 · Cited by 177
“In another study, however, C. auris bloodstream isolates from 18 critically ill patients showed a mean voriconazole MIC of 4 mg/L which is higher than the CLSI breakpoint for other Candida species (≥2 mg/L) (Lockhart et al., 2017).”
BackgroundResultInfluentialYue, H., Bing, J., Zheng, Q., Zhang, Y., Hu, T., Du, H., Wang, H., & Huang, G. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0187-x · Cited by 176
Leach, L., Zhu, Y., & Chaturvedi, S. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01223-17 · Cited by 169
“auris as reported by whole-genome sequencing (4), indicating that it has the potential for broader applications worldwide.”
BackgroundZhu, Y., O’Brien, B., Leach, L., Clarke, A., Bates, M., Adams, E., Ostrowsky, B., Quinn, M., Dufort, E., Southwick, K., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01503-19 · Cited by 162
“auris isolates indicated that the emergence of clonal populations in Asia, South Africa, and South America occurred independently and spread locally within each region (7, 14, 15).”
BackgroundResultA New Age in Molecular Diagnostics for Invasive Fungal Disease: Are We Ready?
Kidd, S. E., Chen, S. C.-A., Meyer, W., & Halliday, C. L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02903 · Cited by 166
“Additionally, WGS identified a specific mutation in the ERG11 gene associated with azole resistance (Lockhart et al., 2017).”
BackgroundEmerging and reemerging fungal infections
Lockhart, S. R., & Guarner, J. (2019) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2019.04.010 · Cited by 169
Self-citationOn the Origins of a Species: What Might Explain the Rise of Candida auris?
Jackson, B. R., Chow, N., Forsberg, K., Litvintseva, A. P., Lockhart, S. R., Welsh, R., Vallabhaneni, S., & Chiller, T. (2019) · Journal of Fungi · doi:10.3390/jof5030058 · Cited by 162
Self-citationBiofilm formation in medically important Candida species
Malinovská, Z., Čonková, E., & Váczi, P. (2023) · Journal of Fungi · doi:10.3390/jof9100955 · Cited by 167
“C. auris has been divided into five geographically and phylogenetically distinct clades (I, II, III, IV, and V) with different sensitivities to antifungal agents, which influences the survival of their biofilms in treated patients [18,83,84].”
BackgroundHealey, K. R., Kordalewska, M., Jiménez Ortigosa, C., Singh, A., Berrío, I., Chowdhary, A., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01427-18 · Cited by 165
“auris is divided into four major clades: South Asian, East Asian, South African, and South American (1).”
BackgroundSelf-citationConfirmation of fifth Candida auris clade by whole genome sequencing
Spruijtenburg, B., Badali, H., Abastabar, M., Mirhendi, H., Khodavaisy, S., Sharifisooraki, J., Taghizadeh Armaki, M., de Groot, T., & Meis, J. F. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2125349 · Cited by 164
“Initial genetic analysis identified four major clades, named after the geographical location: South-Asia, East-Asia, Africa, South America, respectively clade I, II, III and IV [6,7].”
BackgroundSelf-citationThe NDV-3A vaccine protects mice from multidrug resistant Candida auris infection
Singh, S., Uppuluri, P., Mamouei, Z., Alqarihi, A., Elhassan, H., French, S., Lockhart, S. R., Chiller, T., Edwards, J. E., & Ibrahim, A. S. (2019) · PLOS Pathogens · doi:10.1371/journal.ppat.1007460 · Cited by 162
Self-citationTsay, S., Welsh, R. M., Adams, E. H., Chow, N. A., Gade, L., Berkow, E. L., Poirot, E., Lutterloh, E., Quinn, M., Chaturvedi, S., et al. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6619a7 · Cited by 161
“auris isolates were forwarded to CDC for wholegenome sequencing and comparison with previously sequenced international isolates, which clustered into four distinct clades (2).”
MethodSelf-citationContributions of the Biofilm Matrix to Candida Pathogenesis
Nett, J. E., & Andes, D. R. (2020) · Journal of Fungi · doi:10.3390/jof6010021 · Cited by 157
Tsay, S., Kallen, A., Jackson, B. R., Chiller, T. M., & Vallabhaneni, S. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix744 · Cited by 155
“In total, 41% were resistant to ≥2 antifungal classes [8].”
InfluentialSelf-citationGeddes‐McAlister, J., & Shapiro, R. S. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13739 · Cited by 159
Candida auris Forms High-Burden Biofilms in Skin Niche Conditions and on Porcine Skin
Horton, M. V., Johnson, C. J., Kernien, J. F., Patel, T. D., Lam, B. C., Cheong, J. Z. A., Meudt, J. J., Shanmuganayagam, D., Kalan, L. R., & Nett, J. E. (2020) · mSphere · doi:10.1128/msphere.00910-19 · Cited by 159
“auris strains vary genetically and cluster into at least 4 distinct clades (1).”
BackgroundMethodInfluential
Metadata
- Authors
- Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., Berkow, E. L., Castanheira, M., Magobo, R. E., Jabeen, K., Asghar, R. J., Meis, J. F., Jackson, B., Chiller, T., & Litvintseva, A. P.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Aga Khan University (PK)
- University of Delhi (IN)
- National Health Laboratory Service (ZA)
- Universidade Federal de São Paulo (BR)
- Universidad del Zulia (VE)
- Broad Institute (US)
- JMI Laboratories (US)
- Radboud University Nijmegen (NL)
- ORCID
- Lockhart, Shawn R.
- Vallabhaneni, Snigdha
- Farooqi, Joveria
- Chowdhary, Anuradha
- Govender, Nelesh P.
- Colombo, Arnaldo Lopes
- Cuomo, Christina A.
- Desjardins, Christopher A.
- Berkow, Elizabeth L.
- Castanheira, Mariana
- Magobo, Rindidzani E.
- Jabeen, Kauser
- Asghar, Rana J.
- Meis, Jacques F.
- Jackson, Brendan
- Chiller, Tom
- Litvintseva, Anastasia P.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10-20
- Volume
- 64
- Issue
- 2
- Pages
- 134-140
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC5215215
- OpenAlex
- W2536287248
- Semantic Scholar
- c8d8e54651d8fb7a7ece68270cd2630d1cd0df39
- Cited by
- 1,662
- References
- 32
- Citations by year
- 2026: 196 · 2025: 194 · 2024: 203 · 2023: 186 · 2022: 160 · 2021: 178 · 2020: 187 · 2019: 152 · 2018: 116 · 2017: 81 · 2016: 5
- FWCI
- 108.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- public-domain
- Locations
- Clinical Infectious Diseases (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (U19AI110818)
- United States Agency for International Development (4-338/PAK-US/HEC/2010/932)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- Candida auris, multidrug resistance, antifungal resistance, clonal populations, ERG11 mutations, azole resistance, fluconazole resistance, bloodstream infection, invasive candidiasis, nosocomial infections, risk factors, transmission, whole genome sequencing, antifungal susceptibility
- MeSH terms
- Whole Genome Sequencing, Adolescent, Adult, Aged, Antifungal Agents, Candida, Candidiasis, Child, Child, Preschool, Cytochrome P-450 Enzyme System, Female, Humans, Infant, Infant, Newborn, Male, Microbial Sensitivity Tests, Middle Aged, Mutation, Phylogeny, RNA, Ribosomal, 28S, Global Health, Genome, Fungal, Drug Resistance, Multiple, Polymorphism, Single Nucleotide, DNA, Ribosomal Spacer, Drug Resistance, Fungal, Young Adult, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.